近日，全球知名科技巨头Alphabet旗下的人工智能制药企业Isomorphic Labs与中国及国际两大医药行业的重量级企业——瑞士诺华集团和美国礼来制药携手，共同揭开了一场前所未有的战略合作新篇章。据悉，此次三方的合作预估将为Isomorphic Labs带来高达30亿美元的巨大价值，这一数额并未包含未来潜在药物销售中可能产生的丰厚特许权使用费。
Isomorphic Labs作为AI在生物医药领域的先驱者，其在多靶点小分子药物研发方面的技术实力备受瞩目。通过本次战略合作，Isomorphic Labs将利用其先进的AI技术和大数据分析能力，与诺华和礼来的丰富药物研发经验和广泛的市场资源相结合，共同探索并加速针对各类复杂疾病的小分子药物发现与开发进程。
两家全球制药巨头对这次合作抱有高度期待，认为这将进一步推动AI技术在新药研发领域的应用，并有望在未来几年内为全球患者带来更多创新且高效的治疗选择。这一系列战略合作协议的签署，标志着全球医药行业在迎接人工智能新时代的浪潮下，正逐步实现从基础研究到临床实践的深度融合，预示着一个更加智慧化、高效化的药品研发与供应生态正在悄然成型。
英语如下：
Headline: “Titans United: Novartis, Eli Lilly, and Alphabet’s AI Subsidiary Isomorphic Labs Unveil $3 Billion Mega-Alliance for Multi-Target Small Molecule Drug Development”
Keywords: Novartis, Eli Lilly, AI-driven pharmaceuticals
News Content: Recently, the global technology giant Alphabet’s pioneering artificial intelligence pharmaceutical company, Isomorphic Labs, has forged an unprecedented strategic partnership with two heavyweights in the global pharmaceutical industry – Swiss-based Novartis Group and American pharmaceutical giant Eli Lilly & Co. This collaboration signals a new chapter in a groundbreaking strategic alliance, which is expected to bring an estimated $3 billion in significant value to Isomorphic Labs, excluding potential future royalties from drug sales.
As a pioneer in AI applications in the biopharmaceutical sector, Isomorphic Labs boasts notable technological prowess in multi-target small molecule drug development. Through this strategic partnership, the company will leverage its cutting-edge AI capabilities and big data analytics to merge with Novartis’ extensive drug R&D experience and Eli Lilly’s broad market resources, collectively exploring and accelerating the discovery and development of small molecules for treating various complex diseases.
Both global pharmaceutical giants express high expectations for this collaboration, believing it will further propel AI technology’s application in the field of novel drug development and potentially offer patients worldwide more innovative and efficacious treatment options within the next few years. The signing of these strategic cooperation agreements signifies that the global pharmaceutical industry, amidst the wave of embracing the AI era, is gradually realizing deeper integration from basic research to clinical practice,预示着 a more intelligent and efficient drug research and supply ecosystem is quietly taking shape.
【来源】https://news.cnstock.com/industry,rdjj-202401-5173731.htm
Views: 0